Royal Bank of Canada’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,937
| Closed | -$6K | – | 8305 |
|
|
2021
Q3 | $6K | Sell |
2,937
-7,622
| -72% | -$17.7K | ﹤0.01% | 7115 |
|
|
2021
Q2 | $31K | Buy |
10,559
+5,427
| +106% | +$14.3K | ﹤0.01% | 6335 |
|
|
2021
Q1 | $14K | Buy |
5,132
+671
| +15% | +$2.02K | ﹤0.01% | 6662 |
|
|
2020
Q4 | $11K | Buy |
4,461
+4,416
| +9,813% | +$10.6K | ﹤0.01% | 6356 |
|
|
2020
Q3 | $0 | Sell |
45
-17
| -27% | -$57 | ﹤0.01% | 7158 |
|
|
2020
Q2 | $0 | Sell |
62
-1,550
| -96% | -$4.64K | ﹤0.01% | 7082 |
|
|
2020
Q1 | $3K | Sell |
1,612
-2,598
| -62% | -$6.75K | ﹤0.01% | 6244 |
|
|
2019
Q4 | $9K | Buy |
4,210
+3,256
| +341% | +$6.24K | ﹤0.01% | 6203 |
|
|
2019
Q3 | $2K | Sell |
954
-367
| -28% | -$986 | ﹤0.01% | 6350 |
|
|
2019
Q2 | $4K | Buy |
1,321
+412
| +45% | +$1.51K | ﹤0.01% | 6435 |
|
|
2019
Q1 | $5K | Buy |
+909
| New | +$4.48K | ﹤0.01% | 6302 |
|
|
2018
Q2 | – | Sell |
-5
| Closed | – | – | 6900 |
|
|
2018
Q1 | $0 | Sell |
5
-154
| -97% | -$1.15K | ﹤0.01% | 6996 |
|
|
2017
Q4 | $1K | Sell |
159
-1,812
| -92% | -$11.3K | ﹤0.01% | 6456 |
|
|
2017
Q3 | $14K | Buy |
1,971
+1,897
| +2,564% | +$13.1K | ﹤0.01% | 6145 |
|
|
2017
Q2 | $1K | Buy |
+74
| New | +$342 | ﹤0.01% | 6470 |
|
Royal Bank of Canada's SBBP Position: Q4 2021 in Review
Royal Bank of Canada sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 2,937 shares — an estimated $6K sold.
Royal Bank of Canada first reported a position in SBBP in Q2 2017 and held it in 15 quarters. The position peaked at $31K in Q2 2021. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Royal Bank of Canada reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Royal Bank of Canada sold 2,937 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $6K.
- Royal Bank of Canada first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 15 quarters.
- Royal Bank of Canada's Strongbridge Biopharma plc. position peaked at $31K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Royal Bank of Canada's 13F filing for Q4 2021, filed 14 Feb 2022.